化合物 Loxoprofen sodium (dihydrate) T60704
品牌 | 厂商性质 | 产地 | 货期 |
---|---|---|---|
TargetMol | 生产商 | 美国 | 现货 |
性能特点
生化试剂,可用于动物细胞实验
规格 | CAS号 | 价格 | 操作 |
---|---|---|---|
50 mg | 226721-96-6 | ¥13,800.00 | 询底价 |
100 mg | 226721-96-6 | ¥17,500.00 | 询底价 |
25 mg | 226721-96-6 | ¥10,600.00 | 询底价 |
Product Introduction
Bioactivity
英文名: Loxoprofen sodium (dihydrate)
描述: Loxoprofen sodium dihydrate 是一种非甾体类口服抗炎药,具有镇痛和解热作用。Loxoprofen sodium dihydrate 显示出抗肿瘤活性,并且可减少动脉粥样硬化。Loxoprofen sodium dihydrate 是COX 的非选择性抑制剂,对 COX-1 和 COX-2 的IC50值分别为 6.5 和 13.5 μM。
体外活性: Loxoprofen sodium dihydrate, an anti-inflammatory prodrug (NSAID), is a nonselective COX inhibitor with IC 50 s of 6.5 and 13.5 μM for COX-1 and COX-2 in human whole blood assays, respectively [1]. Loxoprofen (LOX) sodium dihydrate is a non-selective cyclooxygenase inhibitor that is widely used for the reasearch of pain and inflammation caused by chronic and transitory conditions. Its alcoholic metabolites are formed by carbonyl reductase (CR) and they consist of trans-LOX, which is active, and cis-LOX, which is inactive. In addition, LOX sodium dihydrate can also be converted into an inactive hydroxylated metabolite (OH-LOXs) by cytochrome P450 (CYP) [2].
体内活性: Loxoprofen sodium (4 mg/kg/day; p.o.; 1 or 8 weeks) dihydrate reduces atherosclerosis in mice by reducing inflammation [3]. Loxoprofen sodium (60 μg/mL; p.o.; 24 days) dihydrate suppresses mouse tumor growth by inhibiting VEGF [4]. Animal Model: ApoE -/- mice (C57BL/6J-Apoe tm1Unc ) with high-fat diet (0.2% cholesterol, 21% saturated fat) from 8 to 16 weeks of age [3] Dosage: 4 mg/kg/day in drinking water Administration: Oral dosing from 8 to 16 weeks of age or from 15 to 16 weeks of age Result: Inhibited platelet thromboxane production and platelet aggregation. Reduced extent of atherosclerosis. Suppressed the production of PGE 2, TxB 2 and PGI 2. Animal Model: 6-week-old male C57BL/6 and BDF1 mice, 100 μL suspensions (2 × 10 6 cells/mL) of LLC cells and KLN205 cells were injected subcutaneously into C57BL/6 and BDF1 mice, respectively [4]. Dosage: 60 μg/mL Administration: Oral dosing in drinking water, every day for 24 days Result: Suppressed tumor growth and angiogenesis, suppressed expression of VEGF in mice with LLC tumor, inhibited tubular formation of HUVECs.
存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
化合物 Loxoprofen sodium (dihydrate) T60704信息由TargetMol中国为您提供,如您想了解更多关于化合物 Loxoprofen sodium (dihydrate) T60704报价、型号、参数等信息,欢迎来电或留言咨询。
注:该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案,不可用于临床诊断或治疗等相关用途